High CBD Mixtures Suppressed Low-THC Strip Responses in a Fortified-Urine Experiment
In fortified urine, a high-CBD mixture produced negative strip results despite added low concentrations of THC-related analytes. That is a possible interference finding, distinct from CBD falsely producing a positive cannabinoid screen.
The investigators tested mixtures outside the body
The study included laboratory tests using three urine lots fortified with cannabinoid groups. These experiments were separate from the oral and topical dosing trial. The low-THC/high-CBD condition combined THC-related analytes at 50 ng/mL with CBD-related analytes at 500 ng/mL. The strips were negative in that condition.
The direction of interference matters
CBD-related fortification alone did not produce positive results under the tested conditions. Most THC-fortified samples were positive, although a low-level replicate was negative. The combined condition therefore raises a different question: whether a mixture can suppress the expected response near the strip’s decision limit. It does not establish that CBD is always a false-positive cross-reactant.
The experiment does not establish a clinical frequency
Known fortification levels do not show how often people reach comparable urinary mixtures. The paper also does not identify this mechanism as the cause of every discrepant result in its participants. A particular negative strip requires the actual kit, specimen and relevant confirmation before interference can be assigned. These were in-vitro analytical observations, not instructions for evading testing or evidence that a negative urine strip proves no exposure. Their value is showing why both false-positive and suppressed-response questions deserve separate examination.
Related analysis: interpreting the study’s urine and plasma findings.
Research cited
Jain and colleagues. Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product: Comparison of Topical and Oral Routes of Administration. Pharmaceuticals (2026). DOI: 10.3390/ph19020231.
